Connection
Mark Gerich to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications Mark Gerich has written about Antibodies, Monoclonal, Humanized.
|
|
Connection Strength |
|
|
|
|
|
0.132 |
|
|
|
-
Scott FI, Luo M, Shah Y, Lasch K, Vajravelu RK, Mamtani R, Fennimore B, Gerich ME, Lewis JD. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis. J Crohns Colitis. 2020 Jun 19; 14(5):575-587.
Score: 0.132